Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
Kristina Hölig(German Red Cross), Johannes Schetelig(University Hospital Carl Gustav Carus), Elke Rücker‐Braun(University Hospital Carl Gustav Carus), Helmuth Schmidt(Cellex Cell Professionals (Germany)), Kristin Zimmer, Gerhard Ehninger(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Alexander H. Schmidt(Deutsche Knochenmarkspenderdatei), Eva Wagner-Drouet(Johannes Gutenberg University Mainz), Katharina Heidrich(University Hospital Carl Gustav Carus), Raphael Teipel(University Hospital Carl Gustav Carus), Rainer Ordemann, Frank Kroschinsky(University Hospital Carl Gustav Carus), Falk Heidenreich(University Hospital Carl Gustav Carus), Gero Hütter, Matthias Blechschmidt, Laszlo Gopsca(National Institute of Oncology), Tigran Torosian(Medical University of Warsaw), Michael Krämer(University Hospital Carl Gustav Carus)
Cited by 0
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402